Radio Surgery is a paid medical program built around Dr. Lederman's recurring case for radiosurgery, screening, and second opinions. It is not a quiet interview show. The episodes move with the pressure and cadence of live radio, stacking ads, disclaimers, location details, patient stories, treatment claims, and calls to action into one continuous argument. Cancer is the center of gravity. Prostate cancer gets the most attention, with repeated discussion of PSA results, Gleason scores, biopsy decisions, recurrence risk, and surgery side effects. The show also covers skin cancers, pancreas cancer, liver and lymph node disease, meningioma, metastatic cancers, and low-dose radiation for arthritis pain. The style is blunt. Dr. Lederman often starts with a patient who went elsewhere, received surgery, chemotherapy, or standard radiation, and then uses that story to argue that better choices may have existed. The result can feel urgent and repetitive, but the repetition is part of the format. It wants the point to land. Listeners hear numbers, treatment comparisons, and quality-of-life language used as persuasion, not detached education. The show regularly frames large hospitals and conventional care pathways as too quick to cut, too narrow in their options, or too confident without enough imaging and second-opinion work. Its medical vocabulary is mixed into everyday speech. Terms like PSA, Gleason, meningioma, basal cell, squamous, metastatic disease, and biliary obstruction sit beside plain warnings about bleeding, incontinence, facial damage, and missed chances. The program is also openly local, returning again and again to Broadway and the idea of picking up information packages. That promotional structure matters. Radio Surgery is best understood as persuasive medical advertising wrapped in case-based commentary. It can be useful for hearing how one cancer-treatment practice talks about options, risks, and outcomes. It should not be mistaken for neutral consensus guidance. The strongest moments come when a specific case opens into a broader question about what patients are told before life-changing treatment. The hardest moments are the heavy claims, repeated phone prompts, and grim descriptions of cancer progression and surgical harm. For the right listener, it is a concentrated dose of second-opinion urgency.